Key Takeaways BrightSpring posted Q4 revenue of $3.55B, up 29.3%, with adjusted EBITDA rising 40.7%.BTSG guides 2026 EBITDA growth of 23%-28%, outpacing revenue growth of 11.9%-16.2%.BrightSpring faces ~$600M revenue headwinds from IRA impacts and generic drug conversions.BrightSpring Health Services, Inc. (BTSG) is coming off a strong finish to 2025, and the market is rewarding that momentum. The stock now trades at 24.5 times forward 12-month earnings per share, raising the key question for investors: is ...

Key Takeaways BrightSpring benefits from care shifting to home settings, supporting demand across its platform.BTSG expects margin gains from mix, automation, and cross-sell despite revenue headwinds.BrightSpring sees ~$600M revenue pressure from IRA impacts and generic drug conversions.BrightSpring Health Services, Inc. (BTSG) is built around a durable healthcare shift: more complex care moving out of hospitals and into the home and community. The company’s 2026 setup pairs that demand tailwind with a prof ...

Core Insights - BrightSpring Health Services, Inc. reported strong financial results for Q4 and full year 2025, driven by high demand for its services and operational capabilities [2][6][10] - The company has provided revenue and Adjusted EBITDA guidance for 2026, excluding the Community Living business [10][11] Financial Highlights - Q4 2025 total revenue reached $3,551 million, a 29% increase from $2,747 million in Q4 2024 [4][6] - Full year 2025 total revenue was $12,911 million, up 28% from $10,072 million in 2024 [4][6] - Adjusted EBITDA for Q4 2025 was $184 million, a 40.7% increase compared to $130 million in Q4 2024 [6][7] - Full year 2025 Adjusted EBITDA was $618 million, up 34.2% from $460 million in 2024 [6][7] Segment Performance - Pharmacy Solutions segment revenue for Q4 2025 was $3,157 million, a 32% increase from $2,397 million in Q4 2024 [4][6] - Provider Services segment revenue for Q4 2025 was $394 million, a 13% increase from $350 million in Q4 2024 [4][6] - Total segment Adjusted EBITDA for Q4 2025 was $227 million, a 35% increase from $168 million in Q4 2024 [7] Business Metrics - The average daily census for Home Health Care increased by 15% to 34,593 in Q4 2025 compared to 30,019 in Q4 2024 [8] - Prescriptions dispensed in Q4 2025 were 10,844,786, a slight decrease of 1% from 10,967,463 in Q4 2024 [8] Guidance for 2026 - The company expects total revenue for 2026 to be between $14,450 million and $15,000 million, representing growth of 11.9% to 16.2% [11] - Pharmacy Segment revenue is projected to be between $12,600 million and $13,100 million, indicating growth of 10.1% to 14.5% [11] - Provider Segment revenue is expected to be between $1,850 million and $1,900 million, reflecting growth of 26.3% to 29.7% [11] - Total Adjusted EBITDA for 2026 is forecasted to be between $760 million and $790 million, representing growth of 23.1% to 27.9% [11]

Core Insights - BrightSpring Health Services Inc. (NASDAQ:BTSG) is recognized as a promising investment opportunity, with BMO Capital initiating coverage with an Outperform rating and a price target of $40 [1] - The company is projected to achieve over 12% EBITDA growth over the next three years, driven by securing additional limited distribution drug contracts and an increase in generic drug conversions [1] Financial Performance - In Q3 2025, BrightSpring Health reported total revenue of $3.3 billion, reflecting a 28% year-over-year increase [2] - Adjusted EBITDA for the same period grew by 37%, reaching $160 million, resulting in an EBITDA margin of 4.8%, which is an increase of 0.3% from the previous year and quarter [2] - The company has raised its full-year 2025 Adjusted EBITDA guidance to a range of $605 to $615 million, indicating a growth of 31.5% to 33.7% compared to full year 2024 [3] - Total revenue for 2025 is expected to be between $12.5 billion and $12.8 billion [3] Business Segments - BrightSpring Health operates as a home and community-based healthcare services platform in the US, with key segments including Pharmacy Solutions and Provider Services [3]

Financial Data and Key Metrics Changes - BrightSpring reported total revenue of $3.3 billion for Q3 2025, representing a 28% year-over-year growth [9][24] - Adjusted EBITDA for the quarter was $160 million, an increase of 37% compared to the same period last year, with an EBITDA margin of 4.8% [9][26] - Cash flow from operations exceeded $100 million in Q3, with leverage declining to 3.3x [10][27] Business Line Data and Key Metrics Changes - Pharmacy Solutions revenue was $3.0 billion, growing 31% year-over-year, while Provider Services revenue reached $367 million, increasing 9% year-over-year [9][24] - Within Pharmacy Solutions, infusion and specialty revenue was $2.4 billion, reflecting a 42% growth from the prior year, while home and community pharmacy revenue was approximately flat at $590 million [24][26] - Provider Services segment adjusted EBITDA grew 16%, with home healthcare revenue increasing 12% year-over-year [18][24] Market Data and Key Metrics Changes - Home healthcare average daily census was 29,592, representing a 3% increase year-over-year, with hospice revenue increasing approximately 15% [18][19] - Specialty pharmacy scripts grew approximately 40% in Q3, driven by strong performance in both brand limited distribution drugs (LDDs) and generics [15][16] Company Strategy and Development Direction - BrightSpring aims to leverage its scaled platform in home and community healthcare to differentiate itself in the market [7] - The company is focused on quality and continuous improvement, with high patient satisfaction scores across service lines [11][12] - Future growth strategies include expanding chronic infused therapy offerings and optimizing go-to-market strategies in pharmacy [17][19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the ongoing operational execution and continuous improvement driving financial results [8] - The company anticipates closing the community living divestiture transaction in Q1 2026, which is subject to regulatory approvals [8][10] - Management expects to achieve adjusted EBITDA guidance of $605 million-$615 million for 2025, reflecting a growth of 31.5%-33.7% over 2024 [30] Other Important Information - BrightSpring will host an Investor Day on March 17 in Louisville to discuss company strategy and service line prospects [21][22] - The company is implementing operational initiatives to enhance efficiency and has seen positive impacts from targeted growth investments [25][88] Q&A Session Summary Question: On the pacing of new drug launches - Management confirmed that the pipeline remains robust, with expectations of 16 to 18 launches over the next 12 to 18 months [32][33] Question: Sources of accretion for the Amedisys transaction - Management indicated that integration of operations and applying best practices will drive incremental margin and profit [41][42] Question: EBITDA per script increase sustainability - Management noted that higher growth in specialty scripts, which have the highest gross profit, contributed to the increase [44][45] Question: Impact of community living divestiture delay - Management stated that the delay is due to regulatory processes but remains optimistic for a Q1 closure [71] Question: Future opportunities in specialty pharmacy - Management highlighted ongoing focus on rare and orphan therapies and the growth potential in both acute and chronic therapies [94][95]

Financial Data and Key Metrics Changes - For Q3 2025, total company revenue was $3.3 billion, representing a 28% increase year over year, with adjusted EBITDA growing approximately 37% to $160 million [9][24][27] - EBITDA margin improved to 4.8%, up 30 basis points compared to the previous year [9][26] - Cash flow from operations exceeded $100 million, and leverage ratio declined to 3.3 times, with a target of 3 times by year-end [10][27] Business Line Data and Key Metrics Changes - Pharmacy Solutions revenue was $3.0 billion, a 31% increase year over year, while Provider Services revenue was $367 million, growing 9% [9][24] - Within Pharmacy Solutions, infusion and specialty revenue reached $2.4 billion, up 42% year over year, while home and community pharmacy revenue was approximately flat at $590 million [24][26] - Provider Services segment adjusted EBITDA grew 16% to $61 million, with home healthcare revenue increasing 12% [18][24] Market Data and Key Metrics Changes - Home healthcare average daily census increased by 3% year over year, with hospice revenue growing approximately 15% [18][19] - Specialty pharmacy scripts grew approximately 40% in Q3, driven by strong performance in both brand limited distribution drugs (LDDs) and generics [15][16] - Home and community pharmacy demonstrated 99.5% order completeness and on-time delivery of 97.2% [12] Company Strategy and Development Direction - The company is focused on quality and continuous improvement, aiming to deliver low-cost, patient-centric care [11][22] - Plans to close the community living divestiture transaction in Q1 2026, which is expected to enhance operational focus [8][29] - The company is optimistic about expanding its presence in targeted markets and enhancing operational efficiency through automation and AI initiatives [84][93] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing growth trajectory, with expectations for continued strong performance in Q4 2025 [10][29] - The company anticipates a positive impact from recent investments in home health, hospice, and rehab services [25][84] - Management remains focused on maintaining high-quality service levels and patient satisfaction across all service lines [11][12] Other Important Information - The company plans to host an Investor Day on March 17 in Louisville to discuss strategy and service line prospects [21] - The adjusted EPS for Q3 was $0.30, reflecting strong operational performance [25] Q&A Session Summary Question: On the pacing of new drug launches - Management confirmed that the pipeline remains robust, expecting 16 to 18 launches over the next 12 to 18 months, with a strong year for brand wins [31][32] Question: On the Amedisys and LHC Home Health Branch acquisitions - Management indicated that the transaction is expected to be accretive in 2026, with integration plans focusing on operational efficiencies [34][36] Question: Sources of accretion from acquisitions - Management highlighted the integration of operations and potential synergies in technology and payer contracts as key sources of incremental margin [40][42] Question: On the sustainability of EBITDA per script growth - Management noted that the increase in EBITDA per script is driven by higher growth in specialty scripts, which have higher gross profit margins [43][45] Question: Impact of community living divestiture delay - Management explained that the delay is due to regulatory processes but remains optimistic for a Q1 closure [68] Question: Future opportunities in specialty pharmacy - Management emphasized ongoing focus on rare and orphan therapies, with expectations for continued growth in the specialty and infusion segments [90][92]

Financial Data and Key Metrics Changes - BrightSpring Health Services reported total revenue of $3.3 billion for Q3 2025, representing a 28% increase year over year [6][21] - Adjusted EBITDA for the quarter was $160 million, reflecting a 37% growth compared to the same period last year [7][24] - The EBITDA margin improved to 4.8%, up approximately 30 basis points year over year [7][24] - Cash flow from operations exceeded $100 million in Q3, with a leverage ratio of 3.3 times at the end of the quarter [8][25] Business Line Data and Key Metrics Changes - Pharmacy Solutions revenue was $3.0 billion, increasing 31% year over year, while Provider Services revenue was $367 million, growing 9% year over year [7][22] - Within Pharmacy Solutions, infusion and specialty revenue reached $2.4 billion, a 42% increase from the prior year, while home and community pharmacy revenue was approximately flat at $590 million [21][22] - Provider Services segment adjusted EBITDA grew 16% to $61 million, with a margin of 16.5%, up 90 basis points year over year [24][16] Market Data and Key Metrics Changes - Home healthcare revenue grew 12% year over year, with an average daily census of 29,592, representing a 3% increase [16][17] - Hospice services saw a 15% increase in revenue year over year, maintaining a high-quality rating [10][16] - The company reported strong growth in specialty scripts, with a 40% increase in Q3, driven by limited distribution drug launches [12][39] Company Strategy and Development Direction - BrightSpring Health Services aims to enhance its position in home and community healthcare, focusing on quality and operational efficiency [5][19] - The company is pursuing acquisitions, including Amedisys and LHC Home Health Branch, expected to close in Q4 2025, which will be neutral to 2025 results but accretive in 2026 [9][33] - The strategy includes expanding into new geographic markets and enhancing chronic therapy offerings [15][80] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing growth trajectory, with expectations for continued strong performance in Q4 2025 [19][72] - The company anticipates achieving a leverage ratio below 3.0 times by year-end, reflecting improved cash flow and operational efficiency [25][74] - Management highlighted the importance of quality metrics and patient satisfaction, which remain high across service lines [10][19] Other Important Information - The community living divestiture is expected to close in Q1 2026, pending regulatory approvals [6][9] - The company is focused on continuous improvement and operational efficiencies, with a new CTO leading AI initiatives [72][80] Q&A Session Summary Question: On the pacing of new drug launches - Management confirmed that the pipeline remains robust, with expectations for 16 to 18 launches over the next 12 to 18 months [30][31] Question: Sources of accretion for the Amedisys transaction - Management indicated that integration will focus on operational efficiencies and leveraging existing practices [34][36] Question: Accretion impact for 2026 - Management stated that the transaction is expected to be accretive in 2026 [33] Question: Growth drivers for specialty pharmacy - Management highlighted strong growth in specialty scripts and the potential for further growth in the infusion market [78][80] Question: Update on M&A pipeline - Management confirmed focus on small, accretive tuck-in deals, with no imminent large transactions [56][57] Question: Impact of community living divestiture delay - Management noted that the process can take time, but they remain optimistic for a Q1 close [61] Question: Future opportunities in pharmacy solutions - Management emphasized growth in rare and orphan therapies, as well as operational efficiencies through automation [78][80]

Core Insights - BrightSpring Health Services, Inc. reported preliminary financial results for Q3 2025, showing significant revenue growth and improved Adjusted EBITDA guidance [1][2][5] Financial Performance - Total revenue for Q3 2025 reached approximately $3,334 million, a 28.2% increase from $2,601 million in Q3 2024 [5][4] - Gross profit for Q3 2025 was approximately $392 million, up 21.3% from $323 million in Q3 2024 [5][4] - The company achieved a net income of approximately $37.5 million in Q3 2025, compared to a net loss of approximately $25.7 million in Q3 2024 [5][4] - Adjusted EBITDA for Q3 2025 was approximately $160 million, reflecting a 37.2% increase from $117 million in Q3 2024 [5][4] Segment Performance - Pharmacy Solutions revenue for Q3 2025 was $2,967 million, a 31% increase from $2,266 million in Q3 2024 [4][5] - Provider Services revenue for Q3 2025 was $367 million, a 9% increase from $336 million in Q3 2024 [4][5] - Total Adjusted EBITDA for the company was $202 million for Q3 2025, up 33% from $151 million in Q3 2024 [6][5] Future Guidance - The company increased its 2025 revenue guidance to between $12,400 million and $12,700 million, representing a growth of 23.1% to 26.1% compared to 2024 [5][4] - Adjusted EBITDA guidance for 2025 is set between $605 million and $615 million, indicating a growth of 31.5% to 33.7% [5][4] Upcoming Events - BrightSpring will announce full Q3 results on October 28, 2025, and will host a conference call at 4:30 p.m. Eastern Time on the same day [3][1]

Core Viewpoint - BrightSpring Health Services Inc. (NASDAQ:BTSG) is identified as a strong growth stock under $30, with a recent price target increase from BofA to $31, maintaining a Buy rating despite concerns over a more negative policy and reimbursement environment [1][3]. Financial Performance - In Q2 2025, BrightSpring Health reported total revenue of $3.1 billion, reflecting a 29% year-over-year increase [2]. - Adjusted EBITDA also increased by 29% to $143 million, while the EBITDA margin remained flat at 4.5% compared to the previous year [2]. - Gross profit for the quarter was $375 million, marking a 20% increase [2]. Segment Performance - The Pharmacy Solutions segment was the main growth driver, with revenue rising 32% year-over-year to $2.8 billion [3]. - Infusion and Specialty Revenue within this segment saw a significant 39% increase, reaching $2.2 billion, while specialty scripts grew by 38% [3]. - Home & Community Pharmacy Revenue grew by 11% to $587 million, contributing to the overall growth in gross profit per script [3]. Company Overview - BrightSpring Health Services operates as a home and community-based healthcare services platform in the US, divided into two segments: Pharmacy Solutions and Provider Services [4].

Company Overview - BrightSpring Health Services Inc. (NASDAQ:BTSG) operates as a home and community-based healthcare services platform in the US, divided into two segments: Pharmacy Solutions and Provider Services [4]. Financial Performance - In Q2 2025, BrightSpring Health reported total revenue of $3.1 billion, reflecting a 29% year-over-year growth, primarily driven by the Pharmacy Solutions segment [2][3]. - The Pharmacy Solutions segment experienced a 32% increase in revenue, reaching $2.8 billion, with infusion and specialty revenue surging by 39% to $2.2 billion and specialty scripts growing by 38% [2][3]. - The Provider Services segment contributed to growth with an 11% revenue increase to $358 million, supported by home healthcare revenue rising 17% to $185 million, rehab revenue increasing by 9% to $73 million, and personal care revenue growing by 4% to $100 million [3]. - Overall gross profit for the company increased by 20% year-over-year to $375 million [3]. Analyst Ratings - Deutsche Bank analyst Pito Chickering raised the price target for BrightSpring Health to $30 from $25 while maintaining a Buy rating on the shares [1][3].